This Promotion Has Ended
Mentorship Resources
Learn about soft skills, industry trends, downloadable toolkits, and more.
Register Now
The CFU Assay: In Vitro Functional Potency Assessment for Hematopoietic Stem and Progenitor Cells
Join our live webinar to learn about the role of CFU assay in evaluating HSPC potency, and how recent regulatory updates emphasize its importance in cellular therapies.
The colony-forming unit (CFU) assay remains the only in vitro assay that provides a correlative assessment of hematopoietic stem and progenitor cell (HSPC) engraftment potential in vivo. For many years, regulatory bodies have recommended functional assessment and the CFU assay for labs working with cellular therapies or transplantable products derived from HSPCs. Recent updates from regulatory bodies such as FACT1 underscore the crucial role of the CFU assay in these workflows, particularly after any processing step, such as cryopreservation, that may impact the functional properties of HSPC products.
In this webinar, we will introduce the utility of the CFU assay for functional assessment of hematopoietic cell products and STEMCELL Technologies’ comprehensive portfolio of reagents, training, and services designed to support high-performing and standardized workflows for hematopoietic cell therapy products.
The CFU Assay: In Vitro Functional Potency Assessment for Hematopoietic Stem and Progenitor Cells
Date: Tuesday, 30 July 2024
Time: 11 a.m. SGT | 1 p.m. AEST
*If you are unable to attend the live webinar, please register and we will send you a link to view the recording when it becomes available.
Topics covered include:
- Understanding the CFU assay and its utility in medical and laboratory workflows for hematopoietic cell transplantation and therapies
- Discovering how the CFU assay assesses the impact of processing on stored units of cord blood
- Exploring methods to standardize and improve CFU assay reproducibility across different personnel and labs
Selena Hallahan is a Product Manager in Hematology at STEMCELL Technologies, where she leads the growth and development of products for HSPC research, including the renowned StemSpan™ and MethoCult™. Selena earned her Master's degree in Drug Design & Biomedical Sciences from Edinburgh Napier University in 2015. Selena then worked for the research charity Myeloma UK, where she supported patients and carers affected by multiple myeloma through patient education initiatives. In 2018, she joined STEMCELL Technologies, where she supports the development of culture media and tools for scientists working with HSPCs.
1Foundation For The Accreditation of Cellular Therapy (FACT) Testing Requirements: "CFU or other validated potency assay must be performed post-processing prior to cryopreservation and on a thawed contiguous segment or representative sample prior to release to the Clinical Program”
